Scarab Genomics signed an exclusive licensing partnership with Bionova Scientific, a CDMO, which gives Bionova the rights to utilize one of Scarab’s proprietary Clean Genome® strains for plasmid DNA (pDNA) production.
Scarab’s Clean Genome platform comprises a library of engineered E. coli strains designed to eliminate mobile genetic elements, minimize genomic instability, and reduce host functions with the goals of higher plasmid yields, improved lot-to-lot consistency, and streamlined downstream purification, according to Venkat Balakrishnan, PhD, director of commercial operations at Scarab. The strain licensed to Bionova incorporates Scarab’s genetic modifications, which reportedly have been optimized specifically for pDNA manufacturing.
“Their [Bionova’s] commitment to supporting innovative therapeutics aligns well with Scarab’s mission to provide high-performance microbial platforms that accelerate development and manufacturing for next-generation biologics,” says Balakrishnan.
The license enables Bionova to integrate the Clean Genome strain into its pDNA production workflows to support client programs across modalities, including mRNA, viral vectors, and emerging genetic medicine platforms, he continues.
“Scarab’s Clean Genome technology strengthens our ability to deliver consistent, scalable, and regulatory-aligned pDNA manufacturing solutions to our customers,” adds Darren Head, president at Bionova.
The post Scarab Genomics and Bionova Partner to Boost Plasmid DNA Production appeared first on GEN – Genetic Engineering and Biotechnology News.
